Anika Therapeutics (ANIK) 50.62 $ANIK Anika to Present

New Post Public Reply Private Reply Replies (0) Message Board

Jun 24, 2016 at 1:08 PM

Anika Therapeutics (ANIK) 50.62 $ANIK

Anika to Present at the Singular Research 11th Annual Spring Select Conference on June 9, 2016
BusinessWire - Thu Jun 02, 3:05PM CDT
Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA"

technology, today announced that its President and Chief Executive Officer, Charles H. Sherwood, Ph.D., will make a presentation at the Singular Research 11th Annual Spring Select Conference on Thursday, June 9, 2016 at 2:30 pm PT. The conference is being held at the Hilton hotel in San Francisco, CA.
ANIK: 50.62 (-0.48)

Anika Announces European Commercial Launch of CINGAL for the Treatment of Pain Associated with Osteoarthritis
BusinessWire - Wed Jun 01, 8:05AM CDT
Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA"

technology, today announced the commercial launch of CINGAL(R), its third-generation viscosupplement, in the European Union. CINGAL, which will be initially available in Hungary, Czech Republic, Poland, Germany, and Italy, received CE Mark approval in March 2016 to treat pain associated with osteoarthritis. CINGAL will be marketed and sold in Europe by a network of experienced commercial partners under the terms of their respective commercialization agreements.
ANIK: 50.62 (-0.48)

Anika Therapeutics Announces Canadian Launch of CINGAL for the Treatment of Pain Associated with Osteoarthritis of the Knee
BusinessWire - Thu May 19, 8:05AM CDT
Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA"

technology, today announced the commercial launch of CINGAL(R), its third-generation viscosupplement, in Canada. CINGAL received Health Canada approval in October 2015 to treat pain associated with osteoarthritis of the knee.
ANIK: 50.62 (-0.48)

Ligand (LGND) Tops Q1 Earnings, Revenues, Updates View
Arpita Dutt - Zacks Investment Research - Thu May 05, 8:36AM CDT
In addition to announcing first quarter results, Ligand (LGND) announced the acquisition of economic rights to several programs owned by CorMatrix.
CBM: 48.76 (-0.75), OMED: 11.95 (-0.82), LGND: 113.20 (-1.91), ANIK: 50.62 (-0.48)

Alexion (ALXN) Lags Q1 Earnings & Revenues, Revises View
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 12:40PM CDT
Alexion (ALXN) reported earnings of 87 cents per share, below the Zacks Consensus Estimate of 91 cents.
EBS: 29.66 (-0.99), ALXN: 111.63 (-11.94), AEGR: 1.58 (-0.09), ANIK: 50.62 (-0.48)

Integra (IART) Beats on Q1 Earnings, Grows Organically
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 12:36PM CDT
Integra LifeSciences Holdings Corporation (IART) reported adjusted earnings per share (EPS) of 74 cents in the first quarter of 2016.
IART: 76.23 (-0.84), ANIP: 54.61 (-1.66), ANIK: 50.62 (-0.48), ALQA: 1.07 (-0.07)

GlaxoSmithKline (GSK) Q1 Earnings Lag, Revenues Up Y/Y
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 12:06PM CDT
Glaxo (GSK) reported first-quarter 2016 core earnings of 57 cents per American depositary share, missing the Zacks Consensus Estimate of 60 cents.
EBS: 29.66 (-0.99), GSK: 41.04 (-1.52), ANIK: 50.62 (-0.48), NVS: 77.84 (-2.83)

Baxalta (BXLT) Beats on Q1 Earnings, Set to Merge with Shire
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 10:41AM CDT
Baxalta's (BXLT) first-quarter 2016 earnings of 47 cents per share beat the Zacks Consensus Estimate by a penny.
BAX: 43.80 (-2.16), SHPG: 166.38 (-13.91), BXLT: 46.02 (-0.18), ANIK: 50.62 (-0.48)

Bristol-Myers (BMY) Tops Q1 Earnings, Updates 2016 View
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 10:27AM CDT
Bristol-Myers' (BMY) first-quarter 2016 earnings (excluding special items) of 74 cents per share easily beat the Zacks Consensus Estimate of 66 cents.
EBS: 29.66 (-0.99), PFE: 34.14 (-0.45), BMY: 70.69 (-1.95), ANIK: 50.62 (-0.48)

Celgene (CELG) Beats on Q1 Earnings, Updates '16 Outlook
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 10:05AM CDT
Celgene Corp. (CELG) reported first-quarter 2016 earnings of $1.18 per share (including share-based compensation expense), beating the Zacks Consensus Estimate of $1.05.
EBS: 29.66 (-0.99), AEGR: 1.58 (-0.09), ANIK: 50.62 (-0.48), CELG: 96.82 (-3.84)

Immunomedics (IMMU) Catches Eye: Stock Moves 10.8% Higher
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 7:15AM CDT
Immunomedics Inc. (IMMU) shares rose almost 11% in the last trading session.
IMMU: 2.30 (-0.20), ANIK: 50.62 (-0.48)

Downgrade Alert for Anika Therapeutics (ANIK)
Comtex SmarTrend(R) - Thu Apr 28, 3:36AM CDT
Anika Therapeutics (NASDAQ:ANIK) was downgraded from Outperform to Market Perform at Northland today. The stock closed yesterday at $44.64 on volume of 513,000 shares, above average daily volume of 148,000. There is potential upside of 14.2% for shares of Anika Therapeutics based on a current price of $44.64 and an average consensus analyst price target of $51.00. Anika Therapeutics shares have support at the 50-day moving average (MA) of $44.62 and additional support at the 200-day MA of $38.85.
ANIK: 50.62 (-0.48)

Anika beats 1Q profit forecasts
Automated Insights - Wed Apr 27, 4:05PM CDT
BEDFORD, Mass. (AP) _ Anika Therapeutics Inc. (ANIK) on Wednesday reported first-quarter earnings of $6.9 million.
ANIK: 50.62 (-0.48)

Anika Reports First Quarter 2016 Financial Results
BusinessWire - Wed Apr 27, 3:05PM CDT
--Commenced $25 million Accelerated Share Repurchase Program
ANIK: 50.62 (-0.48)

Bayer (BAYRY) Q1 Earnings Beat Estimates, Retains View
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 10:57AM CDT
Bayer (BAYRY) reported core earnings of $2.61 per share, above the Zacks Consensus Estimate of $2.48.
CYTX: 1.95 (-0.05), AEGR: 1.58 (-0.09), ANIK: 50.62 (-0.48)

New Strong Buy Stocks for April 27th
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 8:41AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
ALGN: 79.03 (-2.79), AMCX: 57.85 (-1.36), AEGR: 1.58 (-0.09), ANIK: 50.62 (-0.48), ADTN: 17.82 (-0.96)

Oncothyreon (ONTY) Catches Eye: Stock Moves 11.6% Higher
Zacks Equity Research - Zacks Investment Research - Tue Apr 26, 3:31AM CDT
Oncothyreon Inc (ONTY) shares rose almost 12% in the last trading session.
ANIK: 50.62 (-0.48), ONTY: 1.21 (+0.02)

Top 5 Stocks with Increasing Cash Flows
Zacks Equity Research - Zacks Investment Research - Mon Apr 25, 2:24PM CDT
One must look at a company's ability to produce cash - the lifeblood of business.
JBT: 61.39 (-2.14), FOR: 11.78 (-0.56), NSAT: 6.27 (-0.09), EBS: 29.66 (-0.99), ANIK: 50.62 (-0.48)

Biogen (BIIB) Tops on Q1 Earnings, Slight Revenue Miss
Arpita Dutt - Zacks Investment Research - Thu Apr 21, 9:17AM CDT
Biogen's (BIIB) first-quarter earnings were well above expectations though Tecfidera revenues declined sequentially.
BIIB: 230.79 (-7.83), EBS: 29.66 (-0.99), GILD: 80.38 (-2.99), ANIK: 50.62 (-0.48)

Amgen's (AMGN) Phase III Study Results on Nplate Published
Zacks Equity Research - Zacks Investment Research - Wed Apr 20, 10:50AM CDT
Amgen's (AMGN) phase III study results on Nplate in children with symptomatic immune thrombocytopenia were published in The Lancet.
EBS: 29.66 (-0.99), AMGN: 146.55 (-5.72), ANIK: 50.62 (-0.48), NVS: 77.84 (-2.83)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Wally Disrupts Dental Industry with $25M Funding

A New Breath of Fresh Air for Dental Care Dental visits—a tedious, costly affair we've all dreaded. So, when Wally rolls out an overhaul in this stale landscape, it's worth taking notice. With $25 million in their pockets from Series A funding led by Maveron, Wally's swaggering in with a plan to flip the script on dental care across the nation. Redefining the Dental...

Duke Energy's Cost-Protection Plan Shields Ratepayers

Shielding Customers From Data Center Costs Let's get right into the thick of it: Duke Energy's latest move is a strategic one, shrouded in industry terms but with a real impact on regular folks' wallets. The company's agreement with heavyweights like Amazon, Google, and Meta aims to protect existing customers in North Carolina from getting hit with the costs of powering...

Decoding CarBravo-Certified vs Traditional Used Cars

What’s Behind Door Number One: CarBravo Certification When you walk onto a car lot these days, it's a mixed bag: shiny badges boasting certifications or basic used car signage. For anyone who's spent time around cars, two types stick out—there’s your CarBravo-certified vehicles and your good ol' used cars. Now, Marissa McCoy and Jill Maniaci from Heidebreicht...

Ornellaia's 2026 Harvest: Adapting to Nature's Whims

A Year Marked by Weather's Unpredictable Dance Nobody said making wine was a walk in the park, and the folks at Ornellaia know better than most how to roll with whatever nature throws their way. The 2026 harvest story is as much about unlocking the secrets of the soil as it is about navigating the quirks of the weather. Situated in Bolgheri, Italy, this year's vintage...

U. of Phoenix and LACCD Launch 3+1 Degree Pathway

Opening the Floodgates for Ambitious Community College Students When it comes to climbing the educational ladder, not everyone starts at the same rung. That's a fact we've all come to terms with in one way or another. Enter the University of Phoenix and the Los Angeles Community College District with a solution to expand educational access. The 3+1 Program: A Cost-Saving...

OCI N.V. Secures a Win in Court; EGM Proceeds as Planned

OCI Dodges a Bullet in Amsterdam Court Stepping into the courtroom drama, OCI N.V. just took home a win as the Amsterdam Court of Appeal's Enterprise Chamber gave them a clean bill of health, kicking out the inquiry request from VEB and a bunch of other shareholders. The judges weren't convinced there was anything fishy going on, so they tossed the inquiry petition and...

Vitamin Angels Drives Global Nutrition Advancements

Navigating the Waters of Global Nutrition Bet you never thought a vitamin program could spearhead the front lines of healthcare, huh? Vitamin Angels are grinding away under the radar, shifting the landscape for maternal and child nutrition. At the heart of it all is their vision to make UNIMMAP multiple micronutrient supplementation (MMS) a staple in the global playbook....

EMCO's New Automated Facility Could Shake Industry

A Novel Leap in Production Capacity EMCO Industries just put a solid foot on the accelerator with their brand-new, shiny, fully automated plant over in Claremore, Oklahoma. If you're glancing at heavy-duty trailer springs, you can't ignore the fact that this is a multimillion-dollar investment. Heck, this monstrous 30,000-square-foot facility more than doubles what EMCO...

HelloNation Brings 'Edvertising' to NC REALTORS® Event

HelloNation's Bold Step into Real Estate Networking October 8th to the 11th is shaping up to be a pivotal few days in Wilmington, North Carolina. Here’s the scoop: HelloNation, known for its innovative 'edvertising' model, is joining the bustling crowd at the 2026 NC REALTORS® Convention. This isn’t just any get-together—it's the grandest annual jamboree for real...

Merit Expands in New York with Bold Acquisition Move

Merit Financial's Growth Trajectory Takes a Leap You watch the movers and shakers in this game long enough, and you start to see patterns. Merit Financial Advisors is one of those juggernauts you'd better keep an eye on. These folks just scooped up Moldenhauer & Associates—a firm that's been a staple in Orchard Park, New York—for a cool $1.1 billion worth of client...